This study clearly demonstrates that Linagliptin, a well-known DPP-4 inhibitor, can regulate the progression of prostate cancer cells by modulating the PI3k/Akt pathway and its key genes, as illustrated in the schematic presentation (Figure 14). This evidence concerns the gene PIK3CB and prostate cancer.